telitacicept: Clinical Trials

15 trials of telitacicept, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 not yet recruiting, 3 recruiting, 2 completed. 15 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 315Active not recruiting 3, Not yet recruiting 3, Recruiting 3, Completed 2, Unknown 2, Terminated 1, Withdrawn 1
Phase 22Not yet recruiting 1, Unknown 1

Follow telitacicept: new trials by email Literature Review of telitacicept trials Research Report on telitacicept

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
Telitacicept, Placebo - CTD-ILD
Phase 3Not yet recruitingRemeGen Co., Ltd.2602026-04-202026-04-09
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Telitacicept, Placebo - Primary Sjogren's Disease
Phase 3RecruitingVor Biopharma2502026-02-262026-10-19
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
Telitacicept 240mg - Inflammatory Myopathy
Phase 2 / Phase 3Not yet recruitingZhongming Qiu302026-02-022026-01-21
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Telitacicept, Placebo - Myasthenia Gravis, Ocular
Phase 3RecruitingRemeGen Co., Ltd.1202026-01-132026-04-09
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Telitacicept - IgA Nephropathy (IgAN), IgAVN
Phase 3Not yet recruitingGuixia Ding1242025-08-012025-07-10
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
Telitacicept, Placebo - Systemic Lupus Erythematosus
Phase 3WithdrawnVor Biopharma2024-09-012026-01-09
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN)
Phase 3Active not recruitingThe Affiliated Hospital of Xuzhou Medical University1502024-08-012025-08-01
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Telitacicept, Placebo - Generalized Myasthenia Gravis
Phase 3Active not recruitingVor Biopharma1912024-07-172026-10-15
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
Telitacicept - Nephrotic Syndrome in Children, Telitacicept
Phase 3RecruitingThe Children's Hospital of Zhejiang University School of Medicine202023-11-282024-08-21
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Telitacicept, Placebo - Primary IgA Nephropathy
Phase 3Active not recruitingRemeGen Co., Ltd.3182023-04-282025-12-16
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Telitacicept 80 mg, Telitacicept 160 mg, Placebo - Primary Sjogren's Syndrome
Phase 3CompletedRemeGen Co., Ltd.3812023-04-062025-10-01
Study of Telitacicept in Generalized Myasthenia Gravis
Telitacicept, Placebo - Myasthenia Gravis, Generalized
Phase 3CompletedRemeGen Co., Ltd.1142023-03-282025-05-23
Study of Telitacicept in Patients With Refractory IgA Nephropathy
Telitacicept - IgA Nephropathy
Phase 2 / Phase 3UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine402023-03-012023-02-24
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
Telitacicept, Interleukin-2 - Systemic Lupus Erythematosus
Phase 3UnknownLiu Tian602023-02-072024-04-03
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Telitacicept, Placebo - Systemic Lupus Erythematosus
Phase 3TerminatedVor Biopharma912022-06-202026-01-09

Conditions studied

Glomerulonephritis, IGA (4)  ·  Lupus Erythematosus, Systemic (3)  ·  Myasthenia Gravis (3)  ·  Autoimmune Diseases (2)  ·  Immune System Diseases (1)  ·  Muscle Weakness (1)  ·  Myositis (1)  ·  Nephrotic Syndrome (1)  ·  Sjogren's Syndrome (1)

Sponsors

RemeGen Co., Ltd. (5)  ·  Vor Biopharma (4)  ·  Guixia Ding (1)  ·  Liu Tian (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  The Affiliated Hospital of Xuzhou Medical University (1)  ·  The Children's Hospital of Zhejiang University School of Medicine (1)  ·  Zhongming Qiu (1)

Countries

China (10)  ·  United States (4)  ·  Argentina (2)  ·  Australia (2)  ·  Bulgaria (2)  ·  Georgia (2)  ·  Poland (2)  ·  Spain (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  Colombia (1)  ·  Czechia (1)  ·  France (1)

Top investigators

Jianhua Mao, MD (1)  ·  Jicheng Lv, M.D. (1)  ·  Zhanguo Li (1)

Results publications

PMID 38299639, PMID 42127391